All the news Showing 10 of 82 articles from: Protease inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Deaths of Japanese patients prompt label change for simeprevir HCP Live / 24 November 2014 CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe AbbVie press release / 21 November 2014 Merck’s four-week treatment for hepatitis C misses the mark Wall Street Journal / 11 November 2014 Olysio (simeprevir) approved for use in combination with sofosbuvir Johnson & Johnson press release / 07 November 2014 Unique 'pay if you clear' proposal for new hepatitis drug BBC / 15 October 2014 NICE consults on draft guidance on the drug simeprevir (Olysio) for treating hepatitis C NICE / 25 September 2014 AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials HIVandHepatitis.com / 15 September 2014 Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen Bristol-Myers Squibb press release / 08 July 2014 HCV drug out of the running MedPage Today / 23 June 2014 OLYSIO™ available soon in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection Medivir press release / 13 June 2014 ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive